Abstract: The present invention relates to antimicrobial formulations comprising Vitamin D as carrier loaded with an antibiotic. More specifically, the present invention relates to antimicrobial compositions comprising vitamin D as carrier loaded with an antibiotic for controlling infections and managing potentially infected wounds or infected wounds or treating infected implants used in orthopaedic surgery and various other conditions leading to healing of the wounds and avoidance of development of antibacterial resistance and avoiding complications related to the use of prolonged antibiotics by systemic route.

Abstract: The present invention is directed to compounds, compositions, and methods for inhibiting drug-efflux pumps. The compounds, compositions, and methods can be used for enhancing the activity of therapeutic agents that are efflux pump substrates and for the treatment of drug-resistant diseases or disorders, such as microbial infections and cancers.

Abstract: Provided herein are pharmaceutical compositions, each comprising a phenylsulfonamide, for example, a compound of Formula I, or an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; and a pharmaceutically acceptable excipient. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a neurodegenerative disease.

Abstract: Disclosed herein are C-mannoside compounds, compositions thereof and their application as pharmaceuticals for the treatment of human disease. Methods of inhibition of FimH activity in a human subject are also provided for the treatment of diseases such as bacterial infection, Crohn's disease (CD) and Inflammatory Bowel Disease (IBD).

Abstract: This invention relates to antimicrobial gallium compounds, and to monomers containing gallium complex moieties that can be used in oral care products and dental materials, and which can reduce or eliminate dental caries and bacterial or fungal infections associated with medical and dental devices.

Abstract: The invention refers to new methods for treating spontaneous tumors in humans of the Central Nervous System, more particularly of 3rd and 4th grade tumors, even more particularly gliomas, and is related to the administration of compositions comprising therapeutically effective amounts of resveratrolosides and curcumins, in particular natural extracts comprising said two components. The invention also relates to the realization of pharmaceutical and nutraceutleal compositions comprising resveratrolosides and curcumins More specifically, the invention relates to compositions formulated for the release of active components for sublingual administration.

Abstract: Provided herein are methods and uses for treatment or prophylaxis of a senescent cell associated disease or disorder by administering a senolytic combination comprising dasatinib and quercetin or an analog thereof to a subject in need thereof. In certain embodiments, the senescent cell associated disease or disorder is a cardiovascular disease or disorder, inflanunatory disease or disorder, a pulmonary disease or disorder, a neurological disease or disorder, or a metabolic disease or disorder.

Abstract: Provided herein is a topical analgesic composition that includes an external analgesic agent, one or more pharmaceutically acceptable excipients, and at least one of a cannabinoid, terpene, and flavonoid. Also provided is a method that includes topically administering to a skin surface of a subject (e.g., human) the topical analgesic composition.

Abstract: The present invention relates to the novel use of read-through compounds for use in the treatment and/or prevention of Autism Spectrum Disorder.

Abstract: The present invention discloses a fluorescent probe for detecting a sulfenated protein, which has good stability and can specifically quantitatively detect a sulfenated protein in complex biological samples, and has a good detection ability of signal-to-noise ratios, is highly sensitive, and has excellent selectivity, thereby realizing specific detection of sulfhydryl sulfenation modification of intracellular proteins.

Abstract: Compounds, compositions, and methods for treatment and/or prevention of at least one disease, disorder, and/or condition by inhibiting binding of an E-selectin to an E-selectin ligand are disclosed. For example, E-selectin antagonists are described and pharmaceutical compositions comprising at least one of the same.

Abstract: Disclosed herein are new C-mannoside compounds and compositions and their application as pharmaceuticals for the treatment of human disease. Methods of inhibition of FimH activity in a human subject are also provided for the treatment diseases such as urinary tract infection.

Abstract: Compositions comprising at least two of a corticosteroid, a non-steroidal anti-inflammatory drug (NSAID), and an antibiotic find use in treating or preventing eye conditions in subjects in need thereof. Methods of treatment or prevention of eye conditions comprise administering an effective amount of the disclosed compositions to the affected eye(s). Methods of preparing a composition comprising an NSAID, a corticosteroid, and an antibiotic comprise separately complexing the NSAID and antibiotic with cyclodextrin.

Abstract: There is provided herein antibacterial products and processes for preparing antibacterial products from maple syrup and passivating agents in the presence of a catalyst under irradiation or hydrothermal reaction conditions. The disclosure further provides a method for inhibiting the growth of a gram-positive bacteria, a gram-negative bacteria or a yeast.

Abstract: It is to provide an agent for treating and/or ameliorating retinopathy caused by glucose. It is an agent for treating retinopathy caused by glucose comprising sodium/glucose cotransporter2 inhibitor (SGLT2 inhibitor) as an active ingredient, and is used at a normal dosage amount, or at a lower dosage whereby no lowering in blood sugar is observed.

Abstract: Methods are provided herein for preventing, delaying the onset of or reducing the progression of colorectal tumorigenesis in a subject identified as at risk of colorectal tumorigenesis, comprising adjusting the composition of gut microbiota in the subject via administering to the subject a composition comprising Bacteroides bacteria or administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising zwitterionic polysaccharide (ZPS). In another aspect, methods are provided for treating or ameliorating a colorectal cancer in a subject, comprising adjusting the composition of gut microbiota in the subject having the colorectal cancer. In a further aspect, methods are provided for relieving gastrointestinal (GI) distress of a subject having a colorectal condition, comprising: determining the colorectal condition of the subject; and relieving GI distress in the subject by adjusting the composition of gut microbiota in the subject.

Abstract: The present invention provides a class of novel aryl pseudo-C-glycoside compounds that are effective for treating diabetes. Also provided are methods for making such compounds and methods for treating diabetes by administering such compounds to patients who have been diagnosed with diabetes or are at risk of developing diabetes.

Abstract: A compound represented by the formula (1), or a salt thereof (X represents carbonyl group, or sulfonyl group; R1 represents hydrogen atom, a halogen atom, an alkyl group, an alkanoyl group, cyano group, or carboxyl group; R2 represents an alkyl group, a cyclic carbon group, or a heterocyclic group; R3 represents hydrogen atom, or 1 to 3 substituents; R4 and R5 represents hydrogen atom, a halogen atom, or an alkyl group; and R6 represents an alkyl group, or an alkoxy group), which has an mPGES-1 inhibitory action, and is useful as an active ingredient of a medicament for prophylactic and/or therapeutic treatment of inflammation, pain, rheumatism, and the like.

Abstract: The present inventors provides one or more of a tiacumicin compound, a stereo-isomer thereof, a polymorph thereof or a pharmaceutically acceptable solvate thereof for use in the oral treatment of Clostridium difficile infections (CDI) or Clostridium difficile-associated disease (CDAD) in a patient according to a dosage regimen comprising: (1) administering to the patient in an initial course of treatment 200 mg of the tiacumicin compound twice a day; (2) monitoring the efficacy of the initial course of treatment in the patient by means of monitoring changes of one or more indicators of CDI or CDAD; (3) assessing whether there is a positive change of the one or the more of the indicators; and (4) switching to an intermittent course of treatment by administering to the patient 200 mg of the tiacumicin compound every other day if the one or the more of the indicators of CDI or CDAD are positively changed.

Abstract: Compounds, compositions, and methods for treatment and/or prevention of cancer and inflammatory diseases, and for releasing cells such as stem cells (e.g., bone marrow progenitor cells) into circulating blood and enhancing retention of the cells in the blood are disclosed. For example, heterobifunctional compounds that inhibit both E-selectins and CXCR4 chemokine receptors are described and pharmaceutical compositions comprising at least one of the same.

Abstract: A method for extracting stilbene compounds comprises the following steps: grinding a medicinal material rich in stilbene compounds such as rheum officinale; extracting the medicinal material with a herbal flash extractor for one to four times, 5-20 minutes each time; filtering and combining filtrate and concentrating the filtrate to dryness; the proportion of the medicinal material to a solvent being 1 g: 10 ml-1 g:15 ml.

Abstract: Composition, methods of synthesizing trans-arachidin-3; and, methods of use as a dietary supplement, food additive, pharmaceutical, nutraceutical, cosmeceutical, and antioxidant. The methods of production entail organic syntheses using primary alkylamines or primary hydroxyalkyl amines, or carboxy amines (amino acids) with natural carboxylic acids (acetic acid) as catalysts to react isovaleraldehye with trans-resveratrol. The synthesis is carried out in organic solvent, which is composed of an azeotropic mixture comprising toluene with pyridine, n-butanol, n-propanol, 2-propanol, 2-methyl-1-propanol, or other alcohols that form an azeotrope with toluene. The final product is purified and analyzed for the amount of trans-arachidin-3, such as via HPLC, IR, column chromatography, and high-performance counter-current chromatography.

Abstract: A multi-functional composition is disclosed as well as the preparation method and applications thereof. The composition contains a marine algae-derived material and an enzyme inhibitor. The marine algae-derived material is one from the group consisting of natural algal saccharide, alginic acid and alginate or is a mixture of several of them. The enzyme inhibitor is an inhibitor to the enzyme decomposing the material derived from marine algae.

Abstract: Embodiments disclosed herein provide compositions and methods for treating lymphangioleiomyomatosis (LAM) comprising inhibiting COX overexpression and prostaglandin over production by administering at least one COX inhibitor and/or prostaglandin biosynthetic pathway inhibitors. Lymphangioleiomyomatosis (LAM) is a rare lung disease. Some LAM occurances are associated with mutations in the tuberous sclerosis complex (TSC) locus. LAM occurs almost exclusively in women, usually of childbearing age.

Abstract: A pesticidal composition comprising a carboxamide compound represented by following formula (I), wherein R1 represents a hydrogen atom or a methyl group, and R2 represents a methyl group, a difluoromethyl group or a trifluoromethyl group, and one or more carbamate compounds selected from group (A) consisting of oxamyl, thiodicarb, carbosulfan, methiocarb and carbofuran is provided by the present invention, and this composition has an excellent pesticidal effect.

Abstract: Compounds of the formula: are described, along with pharmaceutical compositions containing these compounds, and methods of using the compounds to prevent and to treat cancer in mammals, including humans.

Abstract: Use of cilastatin to reduce the nephrotoxicity of different compounds. The invention refers to use of cilastatin to prepare a medicinal product to reduce the nephrotoxicity of a nephrotoxic compound that enters the cells of the proximal tubule through cholesterol rafts. The invention is based on the discovery that a great number of nephrotoxic compounds, including drugs, enter the cells of the proximal tubule through the cholesterol rafts, and that cilastatin is able to interfere with this transport mechanism, decreasing the nephrotoxicity of such compounds to a variable extent. The nephroprotective effect is common to compounds of different chemical nature and solubility and is specific for the kidney, causing no interference with the effects of nephrotoxic drugs having their targets in other organs. Therefore, administration of cilastatin allows for decreasing the nephrotoxic effects of different drugs without reducing their therapeutic effects.

Abstract: Compounds of formula (I?) wherein: R11, R12, R13, R14 and R15 are hydrogen, hydroxyl, C1-6 alkyl, C1-6 alkoxy, C1-6 alkyl-carbonyloxy, or a G-O— group, and at least one of R11, R12, R13, R14 and R15 is a G-O— group, wherein G is a saccharide residue, X1 is a single bond, or a methylene group, an ethylene group, a trimethylene group, a vinylene group or —CH?CH—CH2—, X2 is —CO—O— or —O—CO—, p and q are integer ofs 0 to 7, and p+q=0 to 8, Y1 is methylene, ethylene or an alkenylene group having a carbon number of 2 to 15 and 1 to 3 double bonds, and R16 and R17 are hydrogen, methyl or ethyl, or R16 and R17 form a C3-6 cycloalkyl group, are useful as GLP-1 secretion promoting agents.

Abstract: A harmful arthropod control composition comprising a compound represented by the following Formula (1) wherein each symbol represents definitions described in the specification, and one or more fungicidal compounds, which are selected from among azoles, strobilurins, phenylamides, rice blast controlling compounds, rice sheath blight disease controlling compounds, and other fungicidal compounds. The composition has an excellent controlling effect against harmful arthropods.

Abstract: Materials and methods are provided for producing and using aptamers useful as oncology therapeutics capable of binding to PDGF, PDGF isoforms, PDGF receptor, VEGF, and VEGF receptor or any combination thereof with great affinity and specificity. The compositions of the present invention are particularly useful in solid tumor therapy and can be used one or in combination with known cytotoxic agents for the treatment of solid tumors. Also disclosed are aptarmers having one or more CpG motifs embedded therein or appended thereto.

Abstract: A process for preparing a biocidal composition comprising the steps of: (i) dissolving at least one polyol in water to form a water/polyol co-solvent solution; (ii) adding at least one organic acid to the water/polyol co-solvent solution; (iii) adding at least one stabiliser to the water/polyol co-solvent solution; (iv) adding a flavonoid composition comprising at least one flavonoid selected from the group consisting of: poncirin, neoeriocitrin, isonaringin, rhoiflin, naringen, neodiosmin, hesperidin, neohesperidin and naringenin.

Abstract: Methods and compositions using E-selectin antagonists are provided for the treatment and prevention of diseases and disorders treatable by inhibiting binding of E-selectin to an E-selectin ligand. Described herein are E-selectin antagonists including, for example, glycomimetic compounds, antibodies, aptamers and peptides that are useful in methods for treatment of cancers, and treatment and prevention of metastasis, inhibiting infiltration of the cancer cells into bone marrow, reducing or inhibiting adhesion of the cancer cells to endothelial cells including cells in bone marrow, and inhibiting thrombus formation.

Abstract: This invention refers to photo-crosslinked hydrogel materials based in gellan gum suitable for tissue engineering and regenerative medicine applications or as drug delivery systems. Formulations of gellan gum with different degrees of acylation serve as precursor material for insertion of a polymerizable moiety. The materials are capable of free radical polymerization with a photo-initiator at mild temperatures and exposure to ultraviolet light, enabling control of reticulation and withstanding the encapsulation of human and animal cells and/or drugs, and any combination thereof. The physicochemical and biological properties can be adjusted by combining different formulations of gellan gum and reaction conditions.

Abstract: The invention relates to novel eucomic acid (2-(4-hydroxybenzyl)malic acid) derivatives or plant extracts comprising such derivatives, and also to cosmetic or dermatological compositions containing these compounds or these extracts, and to cosmetic care methods using said compositions.

Abstract: The present invention provides methods and compositions for modifying fertility in a male mammalian subject by contacting the subject's testis cells, germ cells or sperm with a sufficient amount of a composition comprising a ligand that binds, activates, or inhibits activation of, a TAS2R receptor expressed on the cells. Also described are methods for screening a test molecule for its effect on fertility by examining changes in male germ cells, testis cells or sperm resulting from contact with a molecule that binds, activates, or inhibits activation of, a TAS2R receptor expressed on the cells. Compositions for modifying fertility in a mammalian subject, e.g., contraceptive products, include a ligand that binds, inhibits or activates a TAS2R receptor in a pharmaceutically acceptable carrier.

Abstract: The present invention relates to a method for treating abnormal polyglutamine-mediated diseases comprising: administering a pharmaceutical composition comprising one or more selected from the group consisting of a Gardenia jasminoides extract, geniposide and crocin.

Abstract: Hsp90 C-terminal inhibitors and pharmaceutical compositions containing such compounds are provided. The compounds of the disclosure are useful for the treatment and/or prevention of neurodegenerative disorders such as diabetic peripheral neuropathy.

Abstract: The invention relates to novel fungicidally active compound combinations of 2?-cyano-3,4-dichloroisothiazole-5-carboxanilide and active compounds listed in the disclosure.

Abstract: Compounds, compositions and methods are provided for treatment of diseases or complications associated therewith, in which a selectin plays a role. More specifically, particular glycomimetics and uses thereof are described. For example, use of particular glycomimetics for treating sickle cell disease or a cancer involving a selectin, or complications associated with either, is described.

Abstract: A method for treating an abnormal polyglutamine-mediated disease is disclosed, which comprises: administering a pharmaceutical composition comprising a trehalose-based compound to a subject in need. Additionally, the pharmaceutical composition optionally further comprises a trehalase inhibitor.

Abstract: A hydroxysafflor yellow A sodium compound as shown in a formula (I) and preparation as well as medicinal application thereof are provided. According to the present invention, the safflower is utilized as a raw material. A monomer pharmaceutical compound, the hydroxysafflor yellow A sodium, is obtained by sufficient processes, and a purity thereof is surely above 98.5%. Therefore, the hydroxysafflor yellow A sodium is a monomer compound, which is safer, more effective, more stable and more controllable than hydroxysafflor yellow A, for treating blood circulation disorders such as platelet aggregation, coronary heart disease, angina pectoris and acute cerebral ischemia. Furthermore, the hydroxysafflor yellow A sodium has sufficient solubility and human tolerance.

Abstract: The present invention encompasses compounds and methods for treating urinary tract infections.

Abstract: The 1-aryl-2-aryloxyethane compounds of Formula 1 in which n and m are zero or equal to 1, provided that n+m=1, R1 and R2 in particular representing hydrogen atoms, R3 and R4 in particular representing hydrogen atoms, halogen atoms, hydroxy or alkoxy groups, and R5 in particular representing hydrogen atoms, hydroxy, alkyl, alkoxy, amino or nitro groups, in cosmetic compositions intended for anti-ageing and/or depigmenting and/or anti-inflammatory and/or wound-healing care.

Abstract: Compounds, compositions and methods are provided for inhibiting in vitro and in vivo processes mediated by E-selectin binding. More specifically, particular glycomimetic compounds are described, wherein the compounds are E-selectin antagonists.

Abstract: The present invention relates to an extract of Salix spp obtainable by fractioning on a resin and to the process for its preparation. The extract of the invention is characterized by an high content in salicin derivatives, reduced content in high molecular tannins and a content in proanthocyanidins sufficient to inhibit some tissue metal proteases. The product is formulated in oils rich in ?-3 and ?-6 acids which provide a better absorption of the extract active principles, also increasing synergetically their action.

Abstract: In one aspect, a dry formulation for the effective administration of multiple medications simultaneously for one or more ailments may be provided. The dry formulations include one or more of the following actives in combination with pharmaceutically acceptable excipients or additives: a) at least one antibiotic; b) at least one anti-inflammatory steroid; and c) at least one antifungal agent.

Abstract: The present invention relates to compositions, in particular within a fungicide composition, which comprises (A) a dithiino-tetracarboximide of formula (I) and a further fungicidally active compound (B). Moreover, the invention relates to a method for curatively or preventively controlling the phytopathogenic fungi of plants or crops, to the use of a combination according to the invention for the treatment of seed, to a method for protecting a seed and to the treated seed.

Abstract: The present invention relates to the use of strobilurine type compounds of formula I and the N-oxides and the salts thereof for combating phytopathogenic fungi containing a mutation in the mitochondrial cytochrome b gene conferring resistance to Qo inhibitors, and to methods for combating such fungi. The invention also relates to novel compounds, processes for preparing these compounds, to compositions comprising at least one such compound, to plant health applications, and to seeds coated with at least one such compound.

Abstract: An extract of Andrographis paniculata extract containing androgapholide, 14-deoxyandrographolide, 14-deoxy-11,12-dehydroandrographolide, neoandrographolide, polysaccharides, and flavanoids. Also disclosed is a pharmaceutical composition containing such an extract and its use for treating inflammatory bowel disease.

Abstract: Provided are phenethyl isoindoline compounds, and pharmaceutically acceptable salts, solvates, or stereoisomers thereof. Methods of use and pharmaceutical compositions of these compounds are also disclosed.